@HimanshuNagarMD@Adam_Weiner535@TheLancetOncol Agree with that interpretation! I think a good potential use case could be UIR with goal of avoiding ADT but would need to see how it compares to some form of dose escalation likely microboost
In our latest, a surprise - thanks to computational pathology - about immune cell clustering in prostate cancer and new ways to understand tumors, their neighborhoods, and clinical outcomes ... congrats @DYangMD et al! (link below)
Together, our findings nominate immune spatial clustering as a potential biomarker of clinically meaningful immune enrichment in high-grade localized prostate cancer 6/n
We found that immune cell quantity alone was not associated with outcomes. Instead, a higher burden of spatially dense immune clusters was associated with a lower risk of distant metastasis in two independent cohorts 4/n
We leveraged deep learning analysis of H&E images (obtained as part of routine care) to evaluate whether immune features were associated with outcomes after prostatectomy 3/n
Growing evidence suggests that a subset of prostate cancer is immune-enriched, but the clinical consequences of immune enrichment were largely unknown 2/n